Comment: Sodium-Glucose Cotransporters as Potential Therapeutic Targets in Patients With Type 1 Diabetes Mellitus: An Update on Phase 3 Clinical Trial Data
Restricted accessLetterFirst published online September, 2020
Comment: Sodium-Glucose Cotransporters as Potential Therapeutic Targets in Patients With Type 1 Diabetes Mellitus: An Update on Phase 3 Clinical Trial Data
PatelKCarboneA.Sodium-glucose cotransporters as potential therapeutic targets in patients with type 1 diabetes mellitus: an update on phase 3 clinical trial data. Ann Pharmacother. 2019;53:1227-1237. doi:10.1177/1060028019859323
2.
CureECureMC.Comment on: “High released lactate by epicardial fat from coronary artery disease patients is reduced by dapagliflozin treatment.”Atherosclerosis. 2020;296:2-3. doi:10.1016/j.atherosclerosis.2020.01.006
3.
YassenKAGalleyHFLeeAWebsterNR.Mitochondrial redox state in the critically ill. Br J Anaesth. 1999;83:325-327.
4.
Couselo-SeijasMAgra-BermejoRMFernandezAL, et al. High released lactate by epicardial fat from coronary artery disease patients is reduced by dapagliflozin treatment. Atherosclerosis. 2020;292:60-69. doi:10.1016/j.atherosclerosis.2019.11.016
5.
WuYDongYAtefiMLiuYElshimaliYVadgamaJV.Lactate, a neglected factor for diabetes and cancer interaction. Mediators Inflamm. 2016;2016:6456018. doi:10.1155/2016/6456018
